GlassScriptPhysician profile
Brittany Flaherty
NPI 1922409895
$4,634.66
in general payments reported to CMS, 2019-2025
17 companies · $714 in 2025
The $714 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $131 · 2021: $264 · 2022: $453 · 2023: $1,850 · 2024: $825 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Debt Forgiveness: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.15 |
| Debt Forgiveness | $1,179.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $1,179.75 | 2023 | Panoramic Ophthalmoscope |
| Sun Pharmaceutical Industries INC. | $697.80 | 2021-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $583.74 | 2019-2021 | |
| Lumenis Be INC | $400.00 | 2024 | M22 |
| Bausch & Lomb Americas INC. | $382.40 | 2022-2025 | Miebo, Xiidra, Infuse |
| Tarsus Pharmaceuticals, INC. | $268.50 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $249.03 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $154.52 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $127.39 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Dompe US, INC. | $122.25 | 2023 | Oxervate |
| Biotissue Holdings INC. | $119.12 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $113.19 | 2022 | |
| Maculogix, INC. | $109.42 | 2021 | |
| Alcon Vision LLC | $76.78 | 2019-2025 | Tryptyr |
| Thea Pharma INC. | $19.50 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $16.61 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.